1. World Health Organization. Coronavirus disease (COVID-18) Weekly Epidemiological Update 1. Tersedia di: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6d49a76_4
2 World Health Organization. Interim guidance: Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2. Accessed: 27-February 2020
3. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. The Lancet infectious diseases. 2006 Feb 1;6(2):67-9.
4. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China: A Systematic Review. Journal of medical virology. 2020.
5. Matrosovich M, Herrler G, Klenk HD. Sialic acid receptors of viruses. InSialoGlyco Chemistry and Biology II 2013 (pp. 1-28). Springer, Cham.
6. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020 Feb 4:1-3.
7. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005 Dec 1;2(1):69.
8. Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2020 Oct 8:dkaa403. doi: 10.1093/jac/dkaa403. Epub ahead of print. PMID: 33031488.
9. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for COVID-19-interim WHO SOLIDARITY trial Result. Tersedia di: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
10. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4.23):e208857. Published 2020 Apr 24. doi:10.1001/jamanetworkopen.2020.8857
11. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018 May 2;9(2):e00221-18.
12. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020 Jan 10;11(1):1-4.
13. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar;531(7594):381-5.
14. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;doi:10.1016/S0140-6736(20)31022-9
15. Perhimpunan Dokter Paru Indonesia. Tatalaksana Pasien COVID-19. https://drive.google.com/drive/u/1/folders/1zmyndWKWIuh2PjQ_lzn2SgyvxSejhHyy
16. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia. Pedoman Tatalaksana COVID-19. Tersedia di:https://www.papdi.or.id/pdfs/938/Pedoman%20Tatalaksana%20COVID-19%20edisi%202.pdf
17. WHO. WHO Discontinues Hydroxychloroquine and Lopinavir/ritonavir Treatment Arms for COVID-19. Tersedia: https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
Facebook 
Masuk dengan Email
